

# 해외 바이오의약품 임상 현황 (2019.09.03~2019.09.09)

한국바이오의약품협회, 2019.9.10  
출처: ClinicalTrials.gov

## ○ 미국 15건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04081389	Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer	Anatomic Stage 0 Breast Cancer AJCC v8 Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Early-Stage Breast Carcinoma Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage 0 Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma	Drug: Celecoxib Drug: Cyclophosphamide Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Paclitaxel Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04082572	Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers	High-Frequency Microsatellite Instability Locally Advanced Malignant Solid Neoplasm Loss of MLH1 Expression Loss of MSH2 Expression Loss of MSH6 Expression Loss of PMS2 Expression Mismatch Repair Protein Deficiency	Biological: Pembrolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04050670	A Study of Tirzepatide Concentrations at Different Injection Sites in Participants With Different Body Sizes	Healthy	Drug: Tirzepatide	Eli Lilly and Company	Phase 1
NCT04032418	Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer	Lung Non-Small Cell Carcinoma	Biological: Pembrolizumab	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04019444	Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects	Rabies Rabies Immunisation	Biological: ChAd155-RG Other: Placebo Biological: Rabies Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04008069	Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis	Sarcoidosis	Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], #1 Drug: Placebos	Stanford University	Phase 2
NCT03958045	Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Small Cell Lung Cancer	Combination Product: Rucaparib and Nivolumab	Aman Chauhan University of Kentucky	Phase 2
NCT03947450	Autologous Volar Fibroblast Injection Into the Stump Site of Amputees	Amputation Skin Wound Stem Cell	Biological: Autologous Skin Fibroblasts Biological: Control	Johns Hopkins University	Phase 2
NCT03888105	Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma	Follicular Lymphoma	Drug: REGN1979	Regeneron Pharmaceuticals	Phase 2
NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Acute Bilineal Leukemia Minimal Residual Disease Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myeloproliferative Neoplasm Recurrent Acute Biphentotypic Leukemia Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome	Biological: Rivogenlecleucel Drug: Rimiducid	University of Washington National Cancer Institute (NCI) Bellicum Pharmaceuticals	Phase 1
NCT03571321	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia	Acute Lymphoblastic Leukemia ALL, Childhood ALL	Drug: Ruxolitinib Drug: Cyclophosphamide Drug: Cytarabine Drug: Mercaptopurine Drug: Vincristine Drug: Pegaspargase Drug: Rituximab Drug: Methotrexate (Intrathecal Administration) Drug: Methotrexate (Intravenous Administration) Drug: Dexamethasone Drug: Doxorubicin Drug: Thioguanine Drug: Methotrexate Oral Product	University of Chicago Incyte Corporation	Phase 1
NCT04033432	sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	Castration Levels of Testosterone Castration-Resistant Prostate Carcinoma Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents Metastatic Prostate Adenocarcinoma Progressive Disease Prostate Carcinoma Metastatic in the Bone Prostate Carcinoma Metastatic in the Soft Tissue PSA Progression Stage IVB Prostate Cancer AJCC v8 Testosterone Less Than 50 ng/dL	Biological: Recombinant EphB4-HSA Fusion Protein	Northwestern University Vasgene Therapeutics, Inc National Cancer Institute (NCI)	Phase 2
NCT03872479	Single Ascending Dose Study in Participants With LCA10	Blindness Leber Congenital Amaurosis 10 Vision Disorders Eye Diseases Eye Diseases, Hereditary Eye Disorders Congenital Retinal Disease Retinal Degeneration	Drug: AGN-151587	Allergan Editas Medicine, Inc.	Phase 1 Phase 2
NCT03832998	Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Migraine	Drug: Erenumab Dose 1 Drug: Erenumab Dose 2 Drug: Erenumab Dose 3 Other: Placebo	Amgen	Phase 3
NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	Type 2 Diabetes	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3

## 해외 바이오의약품 임상 현황 (2019.09.03~2019.09.09)

한국바이오의약품협회, 2019.9.10  
출처: ClinicalTrials.gov

### ○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04006808	A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant	Herpes Zoster	Biological: PED-HZ/su	GlaxoSmithKline	Phase 2
NCT03832998	Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Migraine	Drug: Erenumab Dose 1 Drug: Erenumab Dose 2 Drug: Erenumab Dose 3 Other: Placebo	Amgen	Phase 3

### ○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	Type 2 Diabetes	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3

### ○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04078295	A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor	Solid Neoplasms	Drug: E7389-LF Drug: Nivolumab	Eisai Co., Ltd. Ono Pharmaceutical Co. Ltd Eisai Inc.	Phase 1 Phase 2
NCT04077463	A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Japanese Participants With Advanced Non-small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Lazertinib Drug: JNJ-61186372	Janssen Pharmaceutical K.K.	Phase 1
NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	Type 2 Diabetes	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 3